Wednesday, December 9, 2015

Avadim Technologies engages Cantor Fitzgerald as investment banking partner

Avadim Technologies, Inc. (“Avadim”), a life science company delivering Pathogenesis-Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today the engagement of Cantor Fitzgerald, a preeminent capital markets investment bank, to provide strategic and capital markets advisory services. 

Steve Woody, CEO of Avadim Technologies, stated, “We are pleased to have retained Cantor Fitzgerald who is a leading global financial services firm. Cantor’s expertise and proven track record in the healthcare industry will guide us along a path that maximizes shareholder value. Our growth trajectory has positioned our Company to evaluate several strategic options including financing opportunities and an initial public offering in the future. We look forward to working closely with the entire Cantor team going forward. 

About Cantor Fitzgerald: Cantor Fitzgerald, formed in 1945 as an investment bank and brokerage business, became known for its innovation in computer-based bond brokerage, the quality and success of its institutional distribution business model, and as the market’s premier dealer of government securities. Since that time, Cantor has continued to set the pace in innovation to become a premier global financial services firm. Today, Cantor is a preeminent capital markets investment bank, recognized for its strengths in the equity and fixed income capital markets, its global distribution model, and for its expanding presence as the leading independent middle market investment bank serving the marketplace with investment banking services, prime brokerage, and commercial real estate financing. 

For 65 years, Cantor consistently fueled the growth of original ideas, pioneered new markets and provided superior service to clients. Cantor operates trading desks in every major financial center in the world, with offices in over 30 locations around the world and approximately 1,600 employees. As one of the few remaining private partnerships on Wall Street, Cantor has the distinct ability to focus on long-term value creation and solid relationship building. Cantor’s structure allows them to respond quickly to client needs, develop solutions that address complex challenges, avoid the limitations of bureaucracy and attract talented individuals who are driven to succeed.

About Avadim Technologies, Inc.: Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
Avadim Press

No comments: